Andrzej Jakubowiak, MD, PhD | Authors

January 20, 2022

Looking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.

January 14, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

January 10, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, describes how CAR T-cell therapy for patients with heavily pretreated myeloma has the potential significantly impact response and survival outcomes.

January 07, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, talks about daratumumab-based quadruplet therapies being evaluated in clinical trials and the potential impact they’ll have on the multiple myeloma treatment landscape.

November 05, 2021

Concluding their discussion on newly diagnosed multiple myeloma, expert panelists consider treatment options for patients with high-risk disease.

October 29, 2021

Shared insight on the evolving treatment landscape of transplant-ineligible newly diagnosed multiple myeloma.

October 22, 2021

After reviewing the case of a patient with transplant-eligible newly-diagnosed multiple myeloma, experts consider optimal selection of first-line treatment.